Market Size of Global Liver Disease Diagnostics Industry
Study Period | 2019 - 2029 |
Base Year For Estimation | 2023 |
Forecast Data Period | 2024 - 2029 |
CAGR | 5.80 % |
Fastest Growing Market | Asia-Pacific |
Largest Market | North America |
Major Players*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Liver Disease Diagnostics Market Analysis
The liver disease diagnostics market is expected to register a CAGR of 5.8% over the forecast period, 2022-2027.
COVID-19 had a significant impact on the diagnosis and treatment of diseases other than COVID-19 as all the resources were diverted for the COVID-19 patients and also, due to lockdown restrictions and high chances of contracting infection, the footfall in the hospitals and clinics reduced for diseases other than COVID-19 which was expected to have a significant impact on the studied market. However, it was reported that COVID-19 may have a severe impact on people with liver diseases which might have a positive impact on the liver disease diagnostics market. For instance, according to a research study published in May 2021, titled 'Impact of COVID-19 in Liver Disease Progression', the risk of severe COVID-19 was significantly associated with alcoholic liver damage and alcoholic liver cirrhosis, and also, cirrhosis is associated with immune dysfunction, which is related to a bad COVID-19 prognosis. Hence, COVID-19 is anticipated to have an impact on the liver disease diagnostics market.
The major factors that are expected to fuel growth in the liver disease diagnostics market are the increasing consumption of the alcohol and high prevalence of liver diseases around the world. For instance, according to the research study published in June 2021, titled 'Global Epidemiology of Chronic Liver Disease', chronic liver disease (CLD) is one of the leading causes of mortality and morbidity around the world and affects about 1.5 billion people across the world. Further, as per the same source, the most common causes of prevalent disease are non-alcoholic fatty liver disease (NAFLD) (59%), followed by hepatitis B (29%), hepatitis C (9%), and alcoholic liver disease (ALD) (2%). Similarly, according to a research study published in September 2021, titled 'Global Prevalence of Hepatitis B Virus Serological Markers Among Healthcare Workers: A Systematic Review and Meta-Analysis', hepatitis is a global public health issue, and the hepatitis B virus (HBV) infection affects around 2 billion individuals and results in 1 million fatalities each year. Also, as per the same source, healthcare workers (HCWs) are at high risk for HBV because of the occupational risk to patient blood. Hence, due to the high burden of liver diseases, the demand for liver disease diagnostics products is expected to increase which is anticipated to drive growth in the studied market.
In addition, the increasing consumption of alcohol and an associated risk factor for liver disease like obesity is further expected to have a positive impact on the market as these factors are expected to boost the demand for liver disease diagnostics products. For instance, according to a research study published in December 2021, titled 'Effect of Increased Alcohol Consumption During COVID-19 Pandemic on Alcohol-Associated Liver Disease: A Modeling Study', during the COVID-19 pandemic, a temporary rise in alcohol intake can significantly raise long-term ALD-related morbidity and mortality, and it was observed that the alcohol consumption increases up to 25% in the United States. Also, as per the same source, this increase in consumption can lead to 8,000 additional deaths from alcohol-related liver disease, 18,700 cases of liver failure, and 1,000 cases of liver cancer by 2040, which is expected to increase the demand for effective and advanced diagnostic tools so that appropriate medical attention can be provided to the patient. Therefore, due to the above-mentioned factors, the liver disease diagnostics market is expected to grow over the forecast period. However, high costs associated with liver disease tests are expected to restrain the growth of the studied market over the forecast period.
Liver Disease Diagnostics Industry Segmentation
As per the scope of the report, diagnostic procedures for liver disease aid in determining the liver's condition. When liver cells die, their chemical constituents are discharged into the bloodstream, which aids in the detection of liver illness through liver function tests. The liver disease diagnostics market is segmented by diagnosis technique (liver biopsy, imaging tests, liver function tests, and endoscopy), end user (hospitals, laboratories, and other end users), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.
By Diagnosis Technique | |
Liver Biopsy | |
Imaging Tests | |
Liver Function Tests | |
Endoscopy |
By End User | |
Hospitals | |
Laboratories | |
Other End Users |
Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Global Liver Disease Diagnostics Market Size Summary
The liver disease diagnostics market is poised for growth, driven by the increasing prevalence of liver diseases and the rising consumption of alcohol globally. The market is expected to expand due to the high burden of chronic liver conditions, such as non-alcoholic fatty liver disease, hepatitis B, and hepatitis C, which are significant contributors to morbidity and mortality worldwide. The COVID-19 pandemic has also influenced the market, as it highlighted the vulnerabilities of individuals with liver diseases, potentially increasing the demand for diagnostic tools. Despite the challenges posed by the pandemic, such as reduced hospital visits for non-COVID-19 conditions, the need for effective liver disease diagnostics remains critical. The market is characterized by a variety of diagnostic techniques, with imaging procedures like MRI and CT scans expected to see substantial growth due to their high specificity and ability to detect early morphological changes in the liver.
North America is anticipated to dominate the liver disease diagnostics market, supported by a robust healthcare infrastructure and a high prevalence of liver diseases linked to factors such as alcohol consumption and obesity. The United States, in particular, is expected to be a major market due to the significant burden of liver diseases and the introduction of advanced diagnostic tests. The market is moderately competitive, with several key players like Abbott Laboratories, F. Hoffmann-La Roche Ltd, and Siemens Healthcare GmbH actively participating in product development and strategic partnerships to enhance diagnostic capabilities. Innovations such as the Enhanced Liver Fibrosis test and cost-effective screening tools like FibroScan GO are indicative of the ongoing efforts to improve liver health diagnostics. These developments, coupled with increasing health awareness, are likely to drive the market's growth trajectory over the forecast period.
Global Liver Disease Diagnostics Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increase in Alcohol Consumption
-
1.2.2 Increase in Prevalence of Liver Diseases
-
-
1.3 Market Restraints
-
1.3.1 High Cost of Diagnostic Test
-
-
1.4 Porter's Five Force Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD million)
-
2.1 By Diagnosis Technique
-
2.1.1 Liver Biopsy
-
2.1.2 Imaging Tests
-
2.1.3 Liver Function Tests
-
2.1.4 Endoscopy
-
-
2.2 By End User
-
2.2.1 Hospitals
-
2.2.2 Laboratories
-
2.2.3 Other End Users
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Global Liver Disease Diagnostics Market Size FAQs
What is the current Global Liver Disease Diagnostics Market size?
The Global Liver Disease Diagnostics Market is projected to register a CAGR of 5.80% during the forecast period (2024-2029)
Who are the key players in Global Liver Disease Diagnostics Market?
F. Hoffmann-La Roche Ltd, Echosens, Siemens Healthcare GmbH, Boston Scientific Corporation and Thermo Fisher Scientific Inc. are the major companies operating in the Global Liver Disease Diagnostics Market.